ArticleCell biochemistry and biophysics2026
In Vitro Ocular Cytotoxicity of BEE Venom in ARPE-19, NTM5, HCET, and HCEC-12 Cell Lines.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bee venom (BV) is a complex natural secretion of Apis mellifera with documented anti-inflammatory, antimicrobial, and anticancer properties. Despite its therapeutic potential, safety concerns remain due to its strong cytotoxic effects, particularly in sensitive tissues such as the eye. In this study, we evaluated the composition and ocular cytotoxicity of purified BV obtained from the Muğla ecotype of Apis mellifera anatoliaca. High-performance liquid chromatography with variable wavelength detection (HPLC-VWD) confirmed the presence of three principal components; melittin (71.08 ± 0.33%), phospholipase A₂ (12.98 ± 0.27%), and apamin (3.02 ± 0.25%) at retention times consistent with reference standards. Cytotoxicity was assessed in four human ocular cell lines: ARPE-19 (retinal pigment epithelium), NTM5 (trabecular meshwork), HCE-T (corneal epithelium), and HCEC-12 (corneal endothelium), using MTT viability assays and live/dead staining over 24 h and 48 h. BV exerted strong, dose and time dependent cytotoxic effects across all cell lines, with ARPE-19 and NTM5 cells exhibiting the highest sensitivity. IC₅₀ values were 22.36 µg/mL (24 h) and 12.55 µg/mL (48 h) in ARPE-19, and 20.78 µg/mL (24 h) and 13.07 µg/mL (48 h) in NTM5 cells. By contrast, HCEC-12 and HCE-T cells displayed moderate sensitivity, with IC₅₀ values between 29 and 34 µg/mL. These findings highlight tissue-specific differences in BV susceptibility. While BV may offer therapeutic promise, its narrow safety margin in ocular cells underscores the importance of controlled delivery strategies to minimize toxicity. This study provides foundational data for evaluating the ocular safety profile of BV and informs future translational applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.